S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

JNJ Johnson and Johnson

152.06

-0.81 (-0.53%)

Jan 31 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/30/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert J. Decker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson soutient le premier document de consensus canadien qui identifie les écarts critiques dans les soins contre le psoriasis pour les patients de couleur
Thursday 23 January 2025 (1 week ago) • PR Newswire (Canada)

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
Thursday 23 January 2025 (1 week ago) • PR Newswire (US)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Wednesday 22 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]
Wednesday 22 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 22 January 2025 (1 week ago) • Edgar (US Regulatory)

Johnson & Johnson Reports Q4 and Full-Year 2024 Results
Wednesday 22 January 2025 (1 week ago) • Business Wire

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Tuesday 21 January 2025 (2 weeks ago) • PR Newswire (US)

U.S. Stocks Move Sharply Higher, Dow Reaches One-Month Closing High
Friday 17 January 2025 (2 weeks ago) • IH Market News

RYBREVANT® associé à une chimiothérapie approuvé au Canada comme premier et seul traitement ciblé visant à réduire de plus de la moitié le risque de progression de la maladie ou de décès pour le traitement de deuxième intention des patients att
Thursday 16 January 2025 (2 weeks ago) • PR Newswire (Canada)

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer
Thursday 16 January 2025 (2 weeks ago) • PR Newswire (Canada)

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Wednesday 15 January 2025 (2 weeks ago) • PR Newswire (US)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Monday 13 January 2025 (3 weeks ago) • Edgar (US Regulatory)

More Johnson and Johnson News Articles

Amundi Prime All Country...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions